SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Dose Optimization, Part A, and Part B are randomized. Safety Lead-In for Part B is single arm, non-randomized. Part C is non-randomized.
Inclusion Criteria:
Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).
Must have disease with evidence of KRAS G12C mutation.
Must have known programmed death-ligand 1 (PD-L1) expression
Must have measurable disease per RECIST v1.1.
Must have an ECOG performance status of 0 or 1.
Estimated life expectancy ≥12 weeks.
Ability to swallow capsules.
Must have adequate laboratory parameters.
Contraceptive use should be consistent with local regulations for those participating in clinical studies.
Women of childbearing potential must
Exclusion Criteria:
Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.
Have had any of the following prior to randomization:
-- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.
--- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:
Have known active central nervous system metastases and/or carcinomatous meningitis.
Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Huntsville, Alabama 35805, United States
256-705-4224
Tucson, Arizona 85719, United States
Torrance, California 90502, United States
Ocala, Florida 34474, United States
Fort Wayne, Indiana 46845, United States
Indianapolis, Indiana 46202, United States
Minneapolis, Minnesota 55407, United States
Tupelo, Mississippi 38801, United States
Albuquerque, New Mexico 87131, United States
Mineola, New York 11501, United States
Chapel Hill, North Carolina 27599, United States
Columbus, Ohio 43210, United States
Philadelphia, Pennsylvania 19107, United States
Madison, Wisconsin 53715, United States
Yvoir, 5530, Belgium
Rio de Janeiro, 20231-050, Brazil
Rio de Janeiro, 22250-905, Brazil
São José do Rio Preto, 15090000, Brazil
São Paulo, 04039-901, Brazil
Lyon Cedex08, 69373, France
33426556761
Vandœuvre-lès-Nancy, 54511, France
Puducherry, 605006, India
Bologna, 40138, Italy
Verona, 37126, Italy
Nagaizumi-cho,Sunto-gun, 411-8777, Japan
81120023812
Lørenskog, 1478, Norway
0047 679 66 079
Kielce, 25-734, Poland
Deagu, 41404, South Korea
Gangnam-gu, 06273, South Korea
Hospitalet, 08907, Spain
932607744
Changhua County, 50006, Taiwan
+886-4-7238595 ext.3934
Kaohsiung Niao Sung Dist, 83301, Taiwan
+886-7-7317123 ext. 8199
Ankara, 06200, Turkey (Türkiye)
Istanbul, 34722, Turkey (Türkiye)
Izmir, 35360, Turkey (Türkiye)
602-521-3700
520-626-3434
479-872-8130
303-925-0700
475-306-2658
954-450-1808
904-244-4292
352-732-4032
727-344-6569
706-353-2990
404-251-5544
404-251-5544
773-702-9901
317-859-5252
317-621-3858
913-588-6029
859-257-9568
225-215-1185
617-638-7584
781-744-8400
417-882-4880
718-765-2600
212-731-6363
212-731-6363
614-293-3300
541-683-5001
541-789-5003
503-249-3315
803-794-7511
865-305-8780
915-203-2268
713-441-9948
713-792-6363
434-924-4251
804-828-7999
61-03-53208500
07 5202 0000
61392313155
61358323777
6175687000
4355223032681
43 1 27700 2212
032803575
0032 2 434 81 13
056633340
32 16 34 68 02
+3215892040
0032 10 437 298
3255233668
081423351
+5541999744246
558532884576
55991592101
55 41 996379769
55 84 40095595
553534297035
552132076564
557130218735
551149935497
5511999685217
5511985883170
11983591234
551135056616
551144500360
1150840931
4185411000
8615601395554
8613521469355
13675007687
13876825536
13904505825
15963998868
8613601813062
18622221232
420607533688
0320444998
0492031324
33624456290
33240679978
33 1 46 25 24 63
335677718
004930450553044
4937133343550
49990629993911
03617812586
0049 761 27036630
004989857914001
4940280065620
49 6221 3968304
492518352712
0911398114963
4970712982711
302107700220
302105831265
2810-392750
302610999791
302310898607
302312307278
+3614673852
3676516719
09824047561
09448111913
7008651823
9884457106
+919440911865
9769331525
02066455495
02066434366
0542 2517699 ext 1001
9640953911
39 080 5555442
390512142204
390953781496
390223903829
390817770291
00390498215608
390652665698
+39 0332278558
3904518123515
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
+523330447001
3316395372
4776439745
+5215529002732
525552731712
528181431112
+529516035559
82188555
2299314102
0031735532463
0534872610
0031 341 463504
0887531753
0031582863103
31715262950
31107040704
31132213101
31883201410
4755970762
4732000240
4791395554
47 02770
48 41 3674809
48914427209
48563004384
222077500
220039029
40751110005
40721298677
40726273762
40727774974
0724877013
0040745146020
40723401453
01063522096
82319201154
82-2-920-6267
82222284190
82-31-881-8906
924218040
94 60006399
34932483137
34932746085
34928441738
(+34) 913368263
0034913908000
34951308130
34914521987
981950511
955013068
961973500
+34976765746
0046700599120
41522662373
88673121101-5651
0975366098
0424739595
886-23592525(3259)
886-2-2312-3456
886-2-23123456
886-3-5326151 ext 34502
905333616939
90538 609 92 02
05055718475
905555306271
05052312377
905336488217
905336460546
90 5337677131
05344299253
905322480988
05322202675
905324078648
+905327650185
90 532 599 28 25
02038262058